<!-- received="Thu Dec 16 14:41:41 1999 MST" -->
<!-- sent="Thu, 16 Dec 1999 13:39:26 -0800" -->
<!-- name="Max More" -->
<!-- email="max@maxmore.com" -->
<!-- subject="NEWS: Biotech IPO success--molecular evolution" -->
<!-- id="4.2.2.19991216133729.00df5c10@mail.earthlink.net" -->
<!-- inreplyto="" -->
<!-- version=1.10, linesinbody=11 -->
<html><head><title>extropians: NEWS: Biotech IPO success--molecular evolution</title>
<meta name=author content="Max More">
<link rel=author rev=made href="mailto:max@maxmore.com" title ="Max More">
</head><body>
<h1>NEWS: Biotech IPO success--molecular evolution</h1>
Max More (<i>max@maxmore.com</i>)<br>
<i>Thu, 16 Dec 1999 13:39:26 -0800</i>
<p>
<ul>
<li> <b>Messages sorted by:</b> <a href="date.html#3933">[ date ]</a><a href="index.html#3933">[ thread ]</a><a href="subject.html#3933">[ subject ]</a><a href="author.html#3933">[ author ]</a>
<!-- next="start" -->
<li><a href="3934.html">[ Next ]</a><a href="3932.html">[ Previous ]</a>
<!-- nextthread="start" -->
</ul>
<!-- body="start" -->

<p>
Rather unusually for a biotech IPO, today Maxygen went public very 
successfully. They are using directed molecular evolution. The founder has 
also co-founded several other successful companies including Affymetrix. 
Full story:

<p>
<a href="http://www.cnbc.com/commentary/commentary_full_story_stocks.asp?StoryID=9836">http://www.cnbc.com/commentary/commentary_full_story_stocks.asp?StoryID=9836</a>

<p>
Max
<!-- body="end" -->
<p>
<ul>
<!-- next="start" -->
<li><a href="3934.html">[ Next ]</a><a href="3932.html">[ Previous ]</a>
<!-- nextthread="start" -->
</ul>
</body></html>
